Jun 29, 2021
In this space, we’ve talked a great deal about ICER’s failure – often its refusal – to consider the needs and perspectives of patients when determining the value of a new drug or treatment. Patients Rising recently produced a short video about...
Jun 28, 2021
by Terry Wilcox & William Smith June 22, 2021 While the last year was very difficult for millions of Americans, it was also a period of rapid innovation as leaders in government and the private sector worked to combat a global pandemic. As a result, about half the...
Jun 11, 2021
On May 14th, 2021, ICER released a Draft Evidence Report entitled, “JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis.” Patients Rising Now responded to the request for comments on the report. The comments noted that complex health...
May 27, 2021
On May 5, 2021, ICER released its Draft Evidence Report entitled, “Aducanumab for Alzheimer’s Disease.” Patients Rising Now submitted comments on the draft report. As stated in the comments, the goal for researchers and clinicians – and hope for patients – is to...
Mar 18, 2021
As part of the Patient Access and Affordability Project’s ongoing work to hold ICER accountable, we are pleased to announce a new report series, “The Last Word.” In this series, Dr. Paul Langley dissects and refutes the conclusions in ICER’s...
Mar 11, 2021
Comments on ICER’s February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”. Some of the concerns raised in the letter point out that...
